论文部分内容阅读
目的:比较n 68Ga-前列腺特异膜抗原(PSMA)-11 PET/CT与n 18F-脱氧葡萄糖(FDG)PET/CT在前列腺癌根治术前TNM分期中的诊断效能。n 方法:回顾性研究2018年7月至2019年12月间上海交通大学医学院附属仁济医院67例根治性手术病理确诊前列腺癌的患者，年龄(67.5±6.8)岁，均在术前行n 68Ga-PSMA-11 PET/CT与n 18F-FDG PET/CT全身显像。将PET/CT结果与手术病理学检查结果进行对比。采用n χ2检验对比n 68Ga-PSMA-11 PET/CT与n 18F-FDG PET/CT行术前TNM分期的诊断效能，2种显像原发灶最大标准摄取值(SUVn max)的比较行Mann-Whitney n U检验。另将患者分层为低危、中危、高危进行分层分析。n 结果:67例中，低危9例、中危19例、高危39例。对于T分期，88.06%(59/67)的患者n 68Ga-PSMA-11 PET/CT显像阳性，67例中位SUVn max为13.80(7.30，22.40)；46.27%(31/67)的患者n 18F-FDG PET/CT显像阳性，67例中位SUVn max为4.00(3.10，5.60)；2种显像检出的前列腺癌原发灶SUVn max差异有统计学意义(n U＝62，n P<0.05)。分层分析示，n 68Ga-PSMA-11 PET/CT对中危患者的检出率高于n 18F-FDG PET/CT(17/19与6/19; n χ2＝4.920，n P<0.05)。67例中，术后病理示N1期10例。n 68Ga-PSMA-11 PET/CT和n 18F-FDG PET/CT检测阳性区域淋巴结的灵敏度、特异性、准确性、阳性预测值、阴性预测值分别为6/10、87.72%(50/57)、83.58%(56/67)、6/13、92.59%(50/54)和4/10、89.47%(51/57)、82.09%(55/67)、4/10、89.47%(51/57)。n 68Ga-PSMA-11 PET/CT共检出M1期患者15例(22.39%，15/67)，n 18F-FDG PET/CT共判定9例(13.43%，9/67)，二者对远处转移的检出率差异有统计学意义(n χ2＝35.436，n P<0.05)。n 结论:对于前列腺癌T分期，n 68Ga-PSMA-11 PET/CT的检出率在中危患者中优于n 18F-FDG PET/CT。N、M分期时，n 68Ga-PSMA-11 PET/CT的检出率亦高于n 18F-FDG PET/CT。n “,”Objective:To compare the diagnostic efficacy of n 68Ga-prostate specific membrane antigen (PSMA)-11 PET/CT and n 18F-fluorodeoxyglucose (FDG) PET/CT in TNM staging before radical prostatectomy.n Methods:From July 2018 to December 2019, a total of 67 patients ((67.5±6.8) years) with prostate cancer diagnosed pathologically by radical surgery in Renji Hospital, School of Medicine, Shanghai Jiao Tong University were retrospectively enrolled. All patients underwent n 68Ga-PSMA-11 PET/CT and n 18F-FDG PET/CT whole-body scans before surgery. Results of PET/CT were compared with pathological diagnosis after surgery to compare the diagnostic efficiencies of n 68Ga-PSMA-11 PET/CT and n 18F-FDG PET/CT for preoperative TNM staging (n χ2 test). The differences of the maximum standardized uptake value (SUVn max) in primary lesions between 2 imaging methods were compared by Mann-Whitney n U test. Patients were divided into low-risk, intermediate-risk and high-risk for stratified analysis.n Results:Among 67 patients, 9 were with low-risk, 19 were with intermediate-risk, 39 were with high-risk. For T staging, 59 (88.06%, 59/67) patients showed positive results by n 68Ga-PSMA-11 PET/CT imaging, with median SUVn max of 13.80(7.30, 22.40) for 67 patients; 31(46.27%, 31/67) patients showed positive results in n 18F-FDG PET/CT imaging, with median SUVn max of 4.00(3.10, 5.60) (n U=62, n P<0.05). Stratifed analysis showed that the detection rate ofn 68Ga-PSMA-11 PET/CT was higher than that of n 18F-FDG PET/CT in intermediate-risk patients (17/19 n vs 6/19; n χ2=4.920, n P<0.05). Among 67 patients, 10 were diagnosed as N1 stage based on the pathological results. The sensitivities, specificities, accuracies, positive predictive values and negative predictive values ofn 68Ga-PSMA-11 PET/CT and n 18F-FDG PET/CT for detecting positive regional lymph nodes were 6/10, 87.72%(50/57), 83.58%(56/67), 6/13, 92.59%(50/54) and 4/10, 89.47%(51/57), 82.09%(55/67), 4/10, 89.47%(51/57), respectively. n 68Ga-PSMA-11 PET/CT detected 15 patients (22.39%, 15/67) with M1 stage, and n 18F-FDG PET/CT identified 9 patients (13.43%, 9/67; n χ2=35.436, n P<0.05).n Conclusions:As for T staging, the detection rate of n 68Ga-PSMA-11 PET/CT in the intermediate-risk group is better than n 18F-FDG PET/CT. In N and M staging, the detection rates of n 68Ga-PSMA-11 PET/CT are higher than those of n 18F-FDG PET/CT.n